Dr. Sonali Smith discusses the newest developments in the treatment of CML.
Olutasidenib Yields Enduring Remissions in Previously Treated IDH1+ AML
Phase 2 findings support olutasidenib as a potentially “valuable” treatment option in IDH1-mutated acute myeloid leukemia.
Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy
Ahead of the ASCO Annual Meeting, we discuss the assessment and management of cytokine release syndrome in patients with cancer with Elizabeth Shpall, MD.
Novel CDK9 Inhibitor Yields Responses in Relapsed/Refractory AML
Responses with SLS009 were reported at 60 mg once weekly and 30 mg twice weekly for patients with relapsed/refractory acute myeloid leukemia.
Immunotherapy Approaches in AML
Cancer Network sat down with Dr. Naval Daver to discuss advancements and discoveries in immunotherapy for AML patients.
No Major Racial Disparities Reported in Allogeneic Transplant Outcomes
Study authors note that access to multidisciplinary teams and transportation programs may help mitigate hematopoietic cell transplantation outcome disparities.
FDA Grants Accelerated Approval to Ponatinib Combo in Ph+ ALL
Data from the phase 3 PhALLCON trial support the FDA accelerated approval of ponatinib plus chemotherapy in adult patients with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia.
